Kira Holmström
Head of Biomarker Research Herantis
Seminars
Tuesday 3rd February 2026
Panel Discussion: Deciphering the Landscape of Emerging Neurodegenerative Fluid Markers Beyond p-tau & α-Synuclein
9:00 am
- GBA, LRRK2, and TREM2: Where do these emerging targets stand in terms of measurable, scalable biomarkers?
- What should define a ‘clinically useful’ biomarker when translatability remains uncertain?
- How do we ensure fluid biomarkers reflect causal disease biology rather than downstream noise?
Wednesday 4th February 2026
Multi-Protein Panels for Co-Pathology Detection & Biological Patient Stratification; Towards Personalised Medicine in Neuro Trials. Learnings from HER-096 development for Parkinson’s Disease
1:30 pm
- Herantis approach to developing personalised medicine: How can oncology-style biological characterisation help define the right target patient population for disease modifying therapies
- Deep biological characterisation of patients and HER-096 responses across multiple analysis platforms together with digital biomarker readouts
- Including baseline multi‑protein panels to capture copathologies, such as AD pathology
- Potential for novel biomarkers, e.g. skin‑biopsy + seeding assay for less‑invasive stratification tests to boost recruitment
- Learnings for Phase 2 clinical development
